DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies4–7
Proven efficacy regardless of line of
therapy, genetic status and patient
populations8–12
A consistent safety profile
demonstrated across B-cell
malignancies for over 5 years1,12–14
Unmatched BTK inhibitor
dosing flexibility1,15,16